rais pt merger announc ep
invest summari rais pt share
post announc combin gener busi
ow upjohn expect close ep beat
increas pt driven multipl expans ev/ebitda
although think upjohn combin make good
strateg sens remain sidelin see detail specif
opportun drive sale earn growth go forward could
becom construct stock new product opportun
exceed expect and/or gener market improv
takeaway quarter combin upjohn plan
pay dividend free cash flow expect increas
time target new revenu product expect
launch two-third complex gx biosimilar global
key brand row sale
constant currenc cc na sale actual cc basi
eu sale flat cc gener
adjust free cash flow yoy na new product sale
primarili driven fulphila wixela eu unfavor
impact fx off-set new product sale includ hulio tobi
podhal row sale increas result higher volum
exist product primarili driven product sold china new product
sale australia emerg market remain commit
debt paydown end maintain invest grade credit
 report adjust dilut ep factset
estim re-affirmed ep guidanc
factset consensu updat financi model
chang ep estim
 valuat use blend dcf multipl ev/ebitda analysi get
price target
disclosur section may found page
use blend dcf multipl ev/ebitda analysi get price
target
sever potenti upsid downsid risk neutral invest thesi
risk downsid includ follow gener drug price continu declin
could come increas competit key product also custom
consolid given buy consortium power negoti better price
consortium could continu caus price fall lack meaning gener launch
 could make hard off-set sale declin matur product
gener industri product shorter life cycl brand drug gener
part commod busi
risk upsid includ follow could receiv approv launch
gener drugs/new drug anticip brand drug biosimilar
busi may move forward new/bett product anticip
amount chang yoyamount chang yoyvariancecommentstot new product sale fulphila wixela gross repriorit global program time program spend oper non oper pre-tax tax non-oper items- nm- nm- net averag oper cantor fitzgerald research compani estim exhibit catalyst event calendar
exhibit incom statement analysi
exhibit margin analysi
exhibit quarterli sale analysi
exhibit annual sale analysi
exhibit analysi
exhibit balanc sheet analysi
global pharmaceut compani develop licens manufactur market distribut gener brand name over-
the-count over-the-counter product varieti dosag form therapeut categori
